Exploring the multifunctional neuroprotective promise of rasagiline derivatives for multi-dysfunctional Alzheimer's disease
Author(s)
Uddin, Md Sahab
Kabir, Md Tanvir
Rahman, Md Habibur
Alim, Md Abdul
Rahman, Md Motiar
Khatkar, Anurag
Al Mamun, Abdullah
Rauf, Abdur
Mathew, Bijo
Ashraf, Ghulam Md
Griffith University Author(s)
Year published
2020
Metadata
Show full item recordAbstract
Alzheimer's disease (AD) is a chronic, age-related, and irreversible brain disorder that typically devel-ops slowly and gets worse over time. The potent auspicious drug candidate for the treatment of AD is supposed to perform the simultaneous modulation of several targets linked to AD. The new therapeutic approach involves drug candidates that are designed to act on multiple targets and have various pharmacological properties. This trend has triggered the development of various multimodal drugs including TV-3326 (i.e. ladostigil) and M-30 (i.e. a new multitarget iron chelator). TV-3326 combines the neurorestorative/neuroprotective ...
View more >Alzheimer's disease (AD) is a chronic, age-related, and irreversible brain disorder that typically devel-ops slowly and gets worse over time. The potent auspicious drug candidate for the treatment of AD is supposed to perform the simultaneous modulation of several targets linked to AD. The new therapeutic approach involves drug candidates that are designed to act on multiple targets and have various pharmacological properties. This trend has triggered the development of various multimodal drugs including TV-3326 (i.e. ladostigil) and M-30 (i.e. a new multitarget iron chelator). TV-3326 combines the neurorestorative/neuroprotective effects of the cholinesterase (ChE) inhibitory activity of rivastigmine with rasagiline (a selective monoamine oxidase-B inhibitor and novel antiparkinsonian agent) in a single molecule. M-30, the second derivative of rasagiline, was developed by combining the propargyl moiety of rasagiline into the skeleton of VK-28 (i.e. a novel brain permeable neuro-protective iron chelator). It has been revealed that both the compounds possess anti-AD effects and therefore, the clinical development is directed to the treatment of this type of neurodegenerative diseases (NDs). In this article, we have reviewed the neuroprotective molecular mechanisms and multimodal effects of TV-3326 and M-30.
View less >
View more >Alzheimer's disease (AD) is a chronic, age-related, and irreversible brain disorder that typically devel-ops slowly and gets worse over time. The potent auspicious drug candidate for the treatment of AD is supposed to perform the simultaneous modulation of several targets linked to AD. The new therapeutic approach involves drug candidates that are designed to act on multiple targets and have various pharmacological properties. This trend has triggered the development of various multimodal drugs including TV-3326 (i.e. ladostigil) and M-30 (i.e. a new multitarget iron chelator). TV-3326 combines the neurorestorative/neuroprotective effects of the cholinesterase (ChE) inhibitory activity of rivastigmine with rasagiline (a selective monoamine oxidase-B inhibitor and novel antiparkinsonian agent) in a single molecule. M-30, the second derivative of rasagiline, was developed by combining the propargyl moiety of rasagiline into the skeleton of VK-28 (i.e. a novel brain permeable neuro-protective iron chelator). It has been revealed that both the compounds possess anti-AD effects and therefore, the clinical development is directed to the treatment of this type of neurodegenerative diseases (NDs). In this article, we have reviewed the neuroprotective molecular mechanisms and multimodal effects of TV-3326 and M-30.
View less >
Journal Title
Current Pharmaceutical Design
Volume
26
Issue
37
Subject
Pharmacology and pharmaceutical sciences
Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
TV-3326
ladostigil
M-30
cholinesterase inhibitor
monoamine oxidase inhibitor
Alzheimer's disease